Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer
Name
1-s2.0-S2667237522001503-main.pdf
Description
Published version
Size
2.95 MB
Format
Adobe PDF
Checksum (MD5)
e7a2762dca1861164d8a94b75083a812
Author(s)
Connelly, Guinevere G
Kirkland, Orville O
Bohannon, Seven
Lim, Daniel C
Wilson, Robert M
Richards, Edward J
Tay, Dousabel M
Jee, Hyuk
Hellinger, Riley D
Hoang, Ngoc K
Date Issued
2022
Journal
Cell Reports Methods
Publisher
Elsevier BV
Citation
Connelly, Guinevere G, Kirkland, Orville O, Bohannon, Seven, Lim, Daniel C, Wilson, Robert M et al. 2022. "Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer." Cell Reports Methods, 2 (8).
Version
Final published version
Abstract
Neutralizing antibody (NAb) titer is a key biomarker of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but point-of-care methods for assessing NAb titer are not widely available. Here, we present a lateral flow assay that captures SARS-CoV-2 receptor-binding domain (RBD) that has been neutralized from binding angiotensin-converting enzyme 2 (ACE2). Quantification of neutralized RBD in this assay correlates with NAb titer from vaccinated and convalescent patients. This methodology demonstrated superior performance in assessing NAb titer compared with either measurement of total anti-spike immunoglobulin G titer or quantification of the absolute reduction in binding between ACE2 and RBD. Our testing platform has the potential for mass deployment to aid in determining at population scale the degree of protective immunity individuals may have following SARS-CoV-2 vaccination or infection and can enable simple at-home assessment of NAb titer.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/J.CRMETH.2022.100273
